EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act): Epigenomics AG: Places Maximum Number of New Shares in Capital Increase with Pre-emptive Rights

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Restructuring & Recapitalisations/Company Information/molecular
diagnostic 25.01.2013

Not for distribution in the United States

Berlin, Germany, January 25, 2013 - Today the Executive Board of
Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX; ISIN:
DE000A1K0516), with the approval of the Supervisory Board, has taken
the decision to implement the capital increase from authorized
capital, the details of which were announced on January 7, 2013, for
the maximum number of 3,149,430 new ordinary bearer shares,
generating gross proceeds of EUR 4,976,099.

2,811,707 new ordinary bearer shares were taken up by the
shareholders at a subscription price of EUR 1.58 per new share during
the subscription period which started on January 11, 2013 and ended
on January 24, 2013. The remaining 337,723 unsubscribed new shares
were sold at the subscription price of EUR 1.58 per new share in a
private placement to institutional investors. The private placement
was significantly oversubscribed, enabling Epigenomics AG to place
the maximum number of new shares. The capital increase was conducted
by Kempen & Co.

The registration of the implementation of the capital increase with
the commercial register ("Handelsregister") and the admission of the
new shares to the regulated market ("regulierter Markt"), Prime
Standard, of the Frankfurt Stock Exchange are expected on or around
January 29, 2013. Trading in the new shares is expected to begin on
January 30, 2013, and delivery of the new shares to the investors is
expected on January 31, 2013. With the registration of the
implementation of the capital increase the total issued share capital
of Epigenomics increases from EUR 8,818,417.00 to EUR 11,967,847.00.

Epigenomics AG intends to use the net proceeds from the share capital
increase to finance its current operations.

- End of Ad hoc -

Disclaimer

This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities. This document is
not an offer of securities for sale or a solicitation of an offer to
purchase securities in the United States. The shares of Epigenomics
AG (the "Shares") have not been registered under the U.S. Securities
Act of 1933, as amended (the "Securities Act") and may not be offered
or sold in the United States unless registered under the Securities
Act or pursuant to an exemption from such registration. There will be
no public offering of the Shares in the United States and the Shares
will not be registered under the Securities Act.

Contact:

Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English